Horizon Pharma Plc (HZNP)

13.85
0.02 0.14
NASDAQ : Health Technology
Prev Close 13.83
Open 13.84
Day Low/High 13.84 / 14.10
52 Wk Low/High 9.45 / 16.02
Volume 341.10K
Avg Volume 1.78M
Exchange NASDAQ
Shares Outstanding 164.57M
Market Cap 2.18B
EPS -2.50
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Horizon Pharma Gift Establishes First Clinical Team Endowment At Children's National Rare Disease Institute

Horizon Pharma Gift Establishes First Clinical Team Endowment At Children's National Rare Disease Institute

The endowment will support a clinical care team dedicated to providing rare disease patients with earlier intervention and more consistent treatment over the course of their lifetimes

First Week of HZNP May 18th Options Trading

First Week of HZNP May 18th Options Trading

Investors in Horizon Pharma plc saw new options begin trading this week, for the May 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 98 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Horizon Pharma Plc Announces Agreement To License Pre-Clinical Uricase Derivative (MEDI4945) From MedImmune

Horizon Pharma Plc Announces Agreement To License Pre-Clinical Uricase Derivative (MEDI4945) From MedImmune

Agreement Aims to Further Expand Growing Gout Franchise 

Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

Horizon Shares Rise on Q3 Results, Guidance -- Biotech Movers

The Dublin firm on Nov. 6 unveiled third-quarter numbers that topped analysts' estimates and raised its full-year net sales outlook and the lower end of its 2017 adjusted Ebitda guidance.

TheStreet Quant Rating: D (Sell)